The c-Met pathway is a potential target therapy in cancers.172 The activation or hyperresponsiveness of the HGFR/HGF pathway involves two primary mechanisms: mutations in MET within the extracellular or cytoplasmatic domain, resulting in prolonged biochemical signaling, and ligand-independent activation, characterized by the overexpression of the wild-type protein. This evidence concerns the gene MET and cancer.